Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Andy J. Harker"'
Autor:
Victoria J. Barrett, Feng Wang, Christopher Browning, Matthew J Lindon, Henry M. Sarau, James A. Fornwald, Andy J. Harker, Guido Hartmann, Jeffery K. Kerns, David P. Andrew, Graeme Irvine Stevenson, Ashley Paul Hancock, Victoria Vinader, Michael L. Moore, James J. Foley, Jian Jin, Parvathi Rao, Anthony J. Jurewicz, Helen E. Connor, Dwight M. Morrow, Kristen E. Belmonte, Yonghui Wang, Ralph A. Rivero, Cuc Nguyen
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 17:1722-1725
High-throughput screening of the corporate compound collection led to the discovery of a novel series of N-substituted-5-aryl-oxazolidinones as potent human CCR8 antagonists. The synthesis, structure-activity relationships, and optimization of the se
Autor:
Kathrine J. Smith, Roberto Profeta, Simon E. Ward, Marta Neve, Simone Spada, Beatrice Oliosi, Jesper Lund, Andrew Jonathan Harris, Anna Mingardi, Claudette Mookherjee, Stuart P. Ballantine, Rosemary A. Melarange, Laura Aldegheri, Andy J. Harker, Benjamin D. Bax, Mark H Harries, Kevin M. Thewlis, Paul W. Smith, Daniele Andreotti, J. Mosley, Shahnaz P. Yusaf
Publikováno v:
Journal of medicinal chemistry. 53(15)
A series of AMPA receptor positive allosteric modulators has been optimized from poorly penetrant leads to identify molecules with excellent preclinical pharmacokinetics and CNS penetration. These discoveries led to 17i, a potent, efficacious CNS pen
Autor:
Andy J. Harker, Simon Taylor
Publikováno v:
Journal of pharmaceutical and biomedical analysis. 41(1)
Plasma protein binding (PPB) methodology suitable for application in the lead optimisation of a corticosteroid series known to demonstrate non-specific binding (NSB) and poor solubility has been established. The method involved a modification to stan
Autor:
Andy J. Harker, Elizabeth K. Hussey, Susan T. Hall, Mick J. Daniel, Gary L. Evans, Karl H. Donn
Publikováno v:
The Journal of Clinical Pharmacology. 34:975-977
3TC is a dideoxy-nucleoside analogue that has demonstrated in-vitro activity against human immunodeficiency virus (HIV). 3TC concentrations in humans were predicted before the initiation of clinical trials by interspecies scaling of pharmacokinetic p
Autor:
Rupert E. Shaw, Andy J. Harker, Panayiotis Alexandro Procopiou, Michael A. Snowden, Colin M. Burgess, Helen E. Weston, Ashley Paul Hancock, Sarah Walton, Rob J. Stubbs, Rosanne M. Farrell, Richard M. Angell, Chris Ioannou, Onkar M. P. Singh, Wendy R. Irving, Yemisi E. Solanke, Keith Biggadike
Publikováno v:
Journal of medicinal chemistry. 43(1)